Related Experiment Video
Updated: Jul 1, 2026

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Prevention of variceal rebleeding
Jaume Bosch1, Juan Carlos García-Pagán
1Hepatic Haemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clínic, IDIBAPS, University of Barcelona, 08036, Barcelona, Spain. jbosch@medicina.ub.es
Preventing variceal rebleeding in cirrhosis patients can be improved by adding isosorbide-5-mononitrate (ISMN) to beta-blockers for those with inadequate portal pressure reduction. This targeted drug therapy enhances outcomes for high-risk individuals.
Area of Science:
- Hepatology and Gastroenterology
- Clinical Trials and Therapeutics
Background:
- Variceal bleeding is a severe complication of portal hypertension in cirrhosis patients, leading to high rebleeding rates and mortality.
- Current prevention strategies include endoscopic band ligation (EBL), TIPS, and drug therapy with beta-blockers, each with limitations.
- Identifying patients who will benefit from specific drug regimens is crucial for effective rebleeding prevention.
Purpose of the Study:
- To evaluate the efficacy of adding isosorbide-5-mononitrate (ISMN) to beta-blocker therapy in patients with cirrhosis and portal hypertension.
- To determine if monitoring hepatic venous pressure-gradient (HVPG) can guide treatment adjustments for preventing variceal rebleeding.
- To compare the effectiveness of optimized drug therapy with endoscopic band ligation (EBL).
Main Methods:
- Randomized controlled trials comparing EBL with drug therapy (propranolol +/- ISMN) for variceal bleeding survivors.
- Measurement of hepatic venous pressure-gradient (HVPG) to assess portal pressure reduction in response to drug therapy.
- Addition of ISMN to beta-blockers for patients not achieving target HVPG reduction.
Main Results:
- Drug therapy showed similar overall rebleeding rates to EBL (44% vs 54% at 1 year).
- Adding ISMN to beta-blockers improved HVPG reduction in non-responders, significantly lowering rebleeding rates (10% vs 64%).
- No significant differences in survival or non-bleeding complications were observed between treatment groups.
Conclusions:
- Long-term drug therapy, particularly when guided by HVPG monitoring and adjusted with ISMN, is an effective strategy for preventing variceal rebleeding.
- HVPG monitoring is essential for identifying patients who require intensified drug therapy.
- Further trials are needed to establish optimal treatments for non-responders to current drug therapies.
Related Concept Videos
Handwashing II: Pre-procedure and Initial Procedure Steps
The hand washing procedure itself includes the following steps. First, cover cuts, if any, on hands with a waterproof dressing. Cuts and abrasions can become contaminated with bacteria hindering the ability to clean the area thoroughly. In addition, repeated hand washing can worsen an injury. The nails must be short and clean, without nail paint...
Pre-Procedural Guidelines for Assessing Blood Pressure
Epistaxis
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Bleeding in Fresh Concrete
Bleeding can cause several issues in the concrete structure. Sometimes, the rising water gets trapped beneath large aggregate...
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management

